Clinical Trial Update: Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Samarium-153 in combination with Bortezomib in patients with relapsed or refractory multiple myeloma; the study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Bortezomib (bortezomib)
• Samarium-153 (samarium-153)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: COMPLETED